LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Lateral Flow Tests for COVID-19 More Accurate than Previously Reported, Cannot Be Compared to PCR Tests

By LabMedica International staff writers
Posted on 15 Oct 2021
Print article
Image: Lateral Flow Tests for COVID-19 More Accurate than Previously Reported, Cannot Be Compared to PCR Tests (Photo courtesy of Bastion Riccardi (CC 2.0))
Image: Lateral Flow Tests for COVID-19 More Accurate than Previously Reported, Cannot Be Compared to PCR Tests (Photo courtesy of Bastion Riccardi (CC 2.0))

Lateral flow tests (LFTs) for COVID-19 are more accurate than previously reported and cannot be compared directly to how polymerase chain reaction (PCR) tests work, according to new research.

In a study led by the University College London (London, UK), researchers used a new formula to show that LFTs are likely more than 80% effective at detecting any level of COVID-19 infection and likely more than 90% effective at detecting those who are most infectious when using the test. This level of accuracy is much higher than some previous studies have suggested, and the researchers say the tests are a reliable public health tool in stopping the spread of the virus.

According to the researchers, LFTs work in a very different way to PCR tests and cannot be compared ‘like for like’. LFTs detect material from the surface proteins of the virus and are very likely to give a positive result when someone is infectious whereas PCR tests detect the virus’ genetic material, which can be present for weeks after a person is no longer infectious. The researchers have devised a formula for calibrating the sensitivity of LFTs and highlighted their head-to-head validation study that suggested the sensitivity of LFT was only 40%. However, after taking into account the differences between the tests and the biology of COVID-19 the researchers suggest that, in reality, the sensitivity of the typical LFT in being able to identity someone who is likely to be infectious, is above 80%. The researchers have acknowledged that the sensitivity of the LFTs is, of course, dependent on sampling errors and experience of the person performing the sampling and the test and that these uncertainties are not taken into account in their formula calibrations.

“Previous studies comparing the reliability of lateral flow tests and PCR tests could be potentially misleading because a PCR test is a marker of having been infected at some point within a certain window of time and does not necessarily mean someone is infectious when testing positive,” explained lead author, Professor Irene Petersen (UCL Institute of Epidemiology and Health Care). “In most validation studies, individuals were tested simultaneously with LFTs and PCR tests, with PCRs being used as a gold standard to say someone is ‘positive or negative’. The sensitivity of the LFTs was therefore evaluated by their ability to identify the same cases that the PCRs picked up. However, this is like comparing apples and oranges.”

“As LFTs are becoming widely used in schools, workplaces and for admittance to venues such as those used for large events, it is important that health professionals and the public have clear information about the operating characteristics of the tests. We have demonstrated that the absolute sensitivity to detect SARS-CoV-2 antigens is likely high with LFTs,” added Professor Petersen. “To improve our understanding of their characteristics, longitudinal studies where individuals, and ideally contacts of cases, are tested daily by LFTs and PCR tests would help to further understand false negatives (and false positives) and, importantly, the time differences of between turning PCR positive, LFT positive, and symptom onset.”

Related Links:
University College London 

Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Myeloperoxidase Assay
IDK MPO ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.